Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

Novo Nordisk

Status and phase: Completed; Phase 2

Conditions: Chronic Kidney Disease; End-Stage Renal Disease

Treatments: Drug: somatropin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00184652

NN1606-1442

Details and patient eligibility

About

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

Enrollment: 140 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ESRD patients

Exclusion criteria

• Diabetes Mellitus
• Severe and Malignant diseases
• Patients in Intensive Care Units

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind